Overview of Rewind Lb Progress Clinical Research
The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug are capsules that you take with food.
A research study involving human volunteers (also called participants) that is intended to add to medical knowledge. There are two types of clinical studies: interventional studies (also called clinical trials) and observational studies. Another name for an interventional study.
PDF HONIG ET AL REWIND
INTRODUCTION AND OBJECTIVES RewinD-LB phase 2b study (NCT05869669) was initiated to confirm phase 2a results in DLB (Jiang et al, 2022) in which neflamapimod demonstrated positive effects on multiple clinical endpoints, most prominently in patients without evidence of AD co-pathology (assessed by plasma ptau181).
The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 patients with DLB, followed by a 32-week neflamapimod-only treatment Extension phase.
RewinDLB Extension Results Suggest Neflamapimod May Slow DLB Decline ...
< Back to Research April 2, 2025 New RewinD-LB Trial Results Show Promise March 19, 2025 Earlier this month, CervoMed Pharmaceuticals reported data from an open-label extension phase of the RewinD-LB trial suggesting that the study drug, neflamapimod, may slow cognitive decline in dementia with Lewy bodies (DLB). What was the RewinD-LB trial?
The RewinD-LB phase 2b clinical study (NCT05869669) of neflamapimod, targeting cholinergic degeneration, was initiated to confirm phase 2a results, in which neflamapimod demonstrated positive effects in mild-to-moderate DLB on multiple clinical endpoints measuring cognition and/or function, most prominently in patients without elevation in ...
Phase 2A Learnings Incorporated into RewinD
In an exploratory 91-participant phase 2a clinical trial (AscenD- LB , NCT04001517) in dementia with Lewy bodies (DLB), neflamapimod showed improvement over placebo on multiple clinical endpoints. To confirm those results, a phase 2b clinical study ( RewinD-LB , NCT05869669 ) that is similar to AscenD- LB has been initiated.
Background In an exploratory 91-participant phase 2a clinical trial (AscenD- LB , NCT04001517) in dementia with Lewy bodies (DLB), neflamapimod showed improvement over placebo on multiple clinical endpoints. To confirm those results, a phase 2b clinical study ( RewinD-LB , NCT05869669 ) that is similar to AscenD- LB has been initiated. Objectives To optimize the choice of patient population ...
Phase 2A Learnings Incorporated into RewinD
Abstract Background: In an exploratory 91-participant phase 2a clinical trial (AscenD- LB , NCT04001517) in dementia with Lewy bodies (DLB), neflamapimod showed improvement over placebo on multiple clinical endpoints. To confirm those results, a phase 2b clinical study ( RewinD-LB , NCT05869669 ) that is similar to AscenD- LB has been initiated.
New 32‑week extension data from the RewinD‑LB trial suggest neflamapimod may slow cognitive and functional decline in DLB, with biomarker changes indicating reduced brain‑cell degeneration at the intended dose.